09.06.07
QuantRx Biomedical Corporation, Doylestown, PA, an emerging leader in the research and development of medical diagnostic platforms and products, has entered into a long-term agreement with nonwoven roll goods producer Kang Na Hsiung (KNH) of Taiwan. The partnership covers the process development, manufacturing and packaging of its PAD-based product line. KNH’s portfolio targets applications ranging from personal care, hygiene and skin care to industrial specialty products.
According to QuantRx, this milestone will allow the company to rapidly scale the production of its PAD technology products to meet anticipated demand and expanding market reach. This agreement includes its feminine hygiene products and enables QuantRx to seek marketing and distribution agreements with companies in Europe and Asia, and comfortably meet any additional demand.
"KNH has worked closely with us to assure the product is of a quality that will meet global consumer standards," said Bill Fleming, chief scientific officer of QuantRx. "Their support and expertise has been valuable in assuring quality products for our pending launches."
QuantRx anticipates the sale and distribution of its line of feminine hygiene pad products will have a positive impact on its revenue in 2008 and beyond.
According to QuantRx, this milestone will allow the company to rapidly scale the production of its PAD technology products to meet anticipated demand and expanding market reach. This agreement includes its feminine hygiene products and enables QuantRx to seek marketing and distribution agreements with companies in Europe and Asia, and comfortably meet any additional demand.
"KNH has worked closely with us to assure the product is of a quality that will meet global consumer standards," said Bill Fleming, chief scientific officer of QuantRx. "Their support and expertise has been valuable in assuring quality products for our pending launches."
QuantRx anticipates the sale and distribution of its line of feminine hygiene pad products will have a positive impact on its revenue in 2008 and beyond.